DXSE:XETRA:XETRA-Xtrackers - Stoxx Europe 600 Health Care Swap UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 239.45

Change

-1.60 (-0.66)%

Market Cap

USD 0.14B

Volume

2.11K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-23 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.43 (+0.84%)

USD 484.40B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.15 (+0.88%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.26 (+0.97%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.20 (+0.71%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.23 (+0.94%)

USD 157.79B
8R80:XETRA Amundi Index Solutions - Amund..

+0.56 (+0.39%)

USD 98.29B
JARI:XETRA Amundi Index Solutions - Amund..

+0.23 (+0.49%)

USD 98.25B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.45 (+0.88%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+3.72 (+0.69%)

USD 80.38B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.18 (+0.79%)

USD 79.79B

ETFs Containing DXSE:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.32% 81% B- 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.32% 81% B- 79% B-
Trailing 12 Months  
Capital Gain 16.27% 59% D- 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.27% 58% F 59% D-
Trailing 5 Years  
Capital Gain 60.88% 78% C+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 60.88% 77% C+ 75% C
Average Annual (5 Year Horizon)  
Capital Gain 9.08% 68% D+ 66% D+
Dividend Return 9.08% 67% D+ 64% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.67% 65% D 72% C
Risk Adjusted Return 104.71% 97% N/A 97% N/A
Market Capitalization 0.14B 39% F 35% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.